Biolegend, 502526, PerCP/Cyanine5.5 anti-human IFN-γ Antibody, 100tests

Interferon-γ is a potent multifunctional cytokine which is secreted primarily by activated NK cells and T cells. Originally characterized based on anti-viral activities, IFN-γ also exerts anti-proliferative, immunoregulatory, and proinflammatory activities. IFN-γ can upregulate MHC class I and II antigen expression by antigen-presenting cells.
100tests
Verified Reactivity: Human
Reported Reactivity: Chimpanzee, Baboon, Cynomolgus, Rhesus
Antibody Type: Monoclonal
Host Species: Mouse
Immunogen: Partially purified, native human IFN-γ
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation: The antibody was purified by affinity chromatography, and conjugated with PerCP/Cyanine5.5 under optimal conditions.
Concentration: Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application: ICFC - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. * PerCP/Cyanine5.5 has a maximum absorption of 482 nm and a maximum emission of 690 nm.
Excitation Laser: Blue Laser (488 nm)
Application Notes: ELISA or ELISPOT Detection5: The biotinylated 4S.B3 antibody is useful as a detection antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with purified NIB42 antibody (Cat. No. 502402/502404) or purified MD-1 antibody (Cat. No. 507502/507513) as the capture antibody.Flow Cytometry3,4,6-8: The fluorochrome-labeled 4S.B3 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IFN-γ -producing cells within mixed cell populations.Additional reported applications (for the relevant formats) include: neutralization1,2, Western blotting, immunohistochemical staining of paraformaldehyde-fixed, saponin-treated tissue sections, and immunocytochemistry. The 4S.B3 antibody can neutralize the bioactivity of natural or recombinant IFN-γ.Note: For testing human IFN-γ in serum or plasma, BioLegend's ELISA Max™ Sets (Cat. No. 430101 to 430106) are specially developed and recommended.
Application References(PubMed link indicates BioLegend citation): Meager A, et al. 1984. J. Interferon Res. 4:619. (Neut) Meager A, 1987. Lymphokines and Interferons:A Practical Approach. IRL Press Ltd, Oxford, p. 105. (Neut) Sester M, et al. 2002. J. Virol. 76:3748. (ICFC) Infante-Duarte C, et al. 2000 J. Immunol. 165:6107. (ICFC) Goodier M, et al. 2000. J. Immunol. 165:139. (ELISA) Chen H, et al. 2005. J. Immunol. 175:591. (ICFC) Smeltz RB, 2007. J. Immunol. 178:4786. (ICFC) Iwamoto S, et al. 2007. J. Immunol. 179:1449. (ICFC) PubMed Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (ICFC)
Product Citations: Anderson W, et al. 2023. Elife. 12:. PubMed Alves S, et al. 2016. Mol Neurodegener. 58:11. PubMed Hu X, et al. 2022. EBioMedicine. 86:104333. PubMed Saggau C, et al. 2022. Immunity. :. PubMed Lamichhane R, et al. 2020. Eur J Immunol. 50:178. PubMed Bacher P, et al. 2020. Immunity. . PubMed Ibáñez J, et al. 2022. NPJ Vaccines. 7:59. PubMed Bacher P, et al. 2014. J Immunol. 193:3332. PubMed Smith S, et al. 2015. PLoS One. 10: 0138042. PubMed Ebner F, et al. 2020. NPJ Vaccines. 5:25. PubMed Chen Y, et al. 2022. Front Immunol. 13:911050. PubMed Ebner F, et al. 2020. NPJ Vaccines. 5:25. PubMed van der Ploeg K, et al. 2022. Cell Rep Med. 3:100640. PubMed Yang R, et al. 2020. Cell. 183(7):1826-1847.e31. PubMed Cooper GE, et al. 2018. Front Immunol. 9:1671. PubMed Dao LM, et al. 2021. J Neurol. 268:2123. PubMed Creyns B, et al. 2020. Front Immunol. 1.740972222. PubMed Nowak A, et al. 2018. Front Immunol. 0.513194444. PubMed Bacher P, et al. 2013. J Immunol. 190:3967. PubMed Lamichhane R et al. 2019. Cell Rep. 28(12):3061-3076 . PubMed Gamradt S, et al. 2021. iScience. 24:103312. PubMed
RRID: AB_961357 (BioLegend Cat. No. 502525) AB_961355 (BioLegend Cat. No. 502526)
Structure: Cytokine; dimer; 20-25 kD (Mammalian)
Bioactivity: Antiviral/antiparasitic activities; inhibits proliferation; enhances MHC class I and II expression on APC
Cell Sources: CD8+ and CD4+ T cells, NK cells
Cell Targets: T cells, B cells, macrophages, NK cells, endothelial cells, fibroblasts
Receptors: IFN-γRα (CDw119) dimerized with IFN-γRβ (AF-1)
Cell Type: Tregs
Biology Area: Cell Biology, Immunology, Neuroinflammation, Neuroscience
Molecular Family: Cytokines/Chemokines
Antigen References: 1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press, San Diego. 2. De Maeyer E, et al. 1992. Curr. Opin. Immunol. 4:321. 3. Farrar M, et al. 1993. Annu. Rev. Immunol. 11:571. 4. Gray P, et al. 1987. Lymphokines 13:151.
Regulation: Upregulated by IL-2, FGF-basic, EGF; downregulated by vitamin D3 or DMN; labile at pH2
Gene ID: 3458
UniProt: View information about IFN-gamma on UniProt.org
Clone: 4S.B3
Regulatory Status: RUO
Other Names: Interferon-γ, Immune interferon, Type II interferon, T cell interferon, Macrophage-activating factor (MAF), IFN-g, IFN-gamma
Isotype: Mouse IgG1, κ
Q: How stable is PerCP/Cyanine5.5 tandem as compared to PerCP alone?
A: PerCP/Cyanine5.5 is quite photostable and also better than PerCP alone in withstanding fixation.